Finance

Lists
Why is MLTX down 2.63%?
Dive Deeper
MLTX:NASDAQ
MoonLake Immunotherapeutics
$11.47
-2.63%
(-0.31) 1D
$11.46
-0.09% (-0.010)
After hours
Closed: Nov 2, 4:00:02 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MLTX...
Open
$11.80
High
$12.00
Low
$11.17
Mkt. cap
976.17M
Avg. vol.
1.94M
Volume
972.02K
52-wk high
$23.29
52-wk low
$9.46
EPS
-$3.83
Beta
1.09
Shares outstanding
85.11M
No. of employees
130
Open
$11.80
High
$12.00
Low
$11.17
Mkt. cap
976.17M
Avg. vol.
1.94M
Volume
972.02K
52-wk high
$23.29
52-wk low
$9.46
EPS
-$3.83
Beta
1.09
Shares outstanding
85.11M
No. of employees
130
News stories
From web sources and news partners
About MoonLake Immunotherapeutics
CEO-
Employees130
Founded2020
HeadquartersZug, Zug, Switzerland
SectorBiotechnology
Websitemoonlaketx.com
Analyst ratings
Based on 9 analysts giving stock ratings to MLTX in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for MLTX in the last 3 months.
Highest
Current $11.47
$50.00 (+335.92%)
Average
$33.00 (+187.71%)
Lowest
$17.00 (+48.21%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Abrahams
RBC Capital
Hold
Maintained
$17.00
+48.2%
10/27/2026
Yun Zhong
Wedbush
Buy
Maintained
$34.00
+196.4%
10/22/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$50.00
+335.9%
10/05/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
10/01/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
$30.00
+161.6%
10/01/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$33.00
+187.7%
09/30/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$40.00
+248.7%
08/10/2026
Julian Harrison
BTIG
Buy
Maintained
$30.00
+161.6%
08/10/2026
Serge Belanger
Needham
Buy
Maintained
$30.00
+161.6%
08/10/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$70.00
+510.3%
06/22/2026
Richard Law CFA
Goldman Sachs
Sell
Maintained
$12.00
+4.6%
05/11/2026
Andy Chen
Wolfe Research
Buy
Upgraded
$24.00
+109.2%
03/23/2026
Samantha Semenkow
Citi
Sell
Maintained
$6.00
-47.7%
03/20/2026
Qize Ding
Rothschild & Co Redburn
Buy
Upgraded
$40.00
+248.7%
03/19/2026
Alex Thompson CFA
Stifel Nicolaus
Hold
Maintained
$19.00
+65.6%
03/01/2026
Andreas Argyrides
Oppenheimer
Buy
Maintained
$35.00
+205.1%
02/24/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$20.00
+74.4%
02/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
60.64M
56.01M
54.52M
50.22M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.80M
9.21M
15.51M
11.44M
Operating expense
71.43M
65.22M
70.02M
61.66M
Total operating expenses
71.43M
65.22M
70.02M
61.66M
Operating income
-71.43M
-65.22M
-70.02M
-61.66M
Other non operating income
4.32M
3.92M
3.15M
2.87M
EBT including unusual items
-70.58M
-62.77M
-69.08M
-61.72M
EBT excluding unusual items
-70.58M
-62.77M
-69.08M
-61.72M
Income tax expense
115.00K
248.00K
622.00K
90.00K
Effective tax rate
-0.16%
-0.40%
-0.90%
-0.15%
Other operating expenses
-
-
-
-
Net income
-69.73M
-62.43M
-69.71M
-61.80M
Net profit margin
-
-
-
-
Earnings per share
-1.10
-0.92
-0.98
-0.84
Interest and investment income
-
-
-
-
Interest expense
-3.20M
-1.99M
-2.27M
-2.63M
Net interest expenses
-3.20M
-1.99M
-2.27M
-2.63M
Depreciation and amortization charges
-
-
-
-
EBITDA
-70.69M
-64.47M
-69.18M
-60.76M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps